Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
148 INR | +1.61% | +0.27% | +6.63% |
May. 14 | Jefferies Adjusts Piramal Pharma’s Price Target to INR180 From INR170, Keeps at Buy | MT |
May. 13 | Transcript : Piramal Pharma Limited, Q4 2024 Earnings Call, May 13, 2024 |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 48% by 2026.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The company does not generate enough profits, which is an alarming weak point.
- The group shows a rather high level of debt in proportion to its EBITDA.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 197.4 times its estimated earnings per share for the ongoing year.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+6.63% | 2.35B | - | ||
+40.73% | 739B | C+ | ||
+32.83% | 598B | B | ||
-6.30% | 353B | C+ | ||
+15.15% | 318B | B- | ||
+4.05% | 285B | C+ | ||
+15.00% | 240B | B+ | ||
+9.78% | 210B | B- | ||
-5.52% | 206B | A+ | ||
+6.17% | 164B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- PPLPHARMA Stock
- Ratings Piramal Pharma Limited